GE HealthCare Technologies Inc.
GEHC Healthcare Medical - Healthcare Information Services NASDAQ
$80.69
+$0.92 (+1.16%)
Open: $79.77 | High: $81.01 | Low: $79.52 | Prev Close: $79.77
Market Cap: $36.84B
Volume: 1.0M | Avg: 4.1M
Last updated: January 26, 2026 at 06:02 PMFeatured In
This stock appears in the following dashboards:
Options Activity for GEHC
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 330
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 16.71 |
| P/B Ratio | 3.69 |
| P/S Ratio | 1.82 |
| EPS | $4.83 |
| Beta | 1.23 |
| Shares Outstanding | 456.56M |
| 52-Week High | $94.80 |
| 52-Week Low | $57.65 |
| SMA 50 | $81.34 |
| SMA 200 | $74.91 |
| Dividend Yield | 0.17% |
| Annual Dividend | $0.14 |
| Next Earnings | February 04, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 40.8% |
| Operating Margin | 13.5% |
| Net Margin | 10.9% |
| ROE | 23.7% |
| ROA | 6.1% |
| Debt/Equity | 1.08 |
| Current Ratio | 1.18 |
| Quick Ratio | 0.95 |
Balance Sheet
| Total Assets | $33.09B |
| Total Liabilities | $24.44B |
| Total Equity | $8.45B |
|
|
|
| Cash | $2.89B |
| Total Debt | $9.38B |
| Net Debt | $6.49B |
Income Statement
| Revenue | $19.67B |
| Gross Profit | $8.21B |
| Operating Income | $2.62B |
| Net Income | $1.99B |
|
|
|
| EBITDA | $3.67B |
| Revenue/Share | $44.40 |
Cash Flow
| Operating CF | $1.95B |
| CapEx | $401.00M |
| Free Cash Flow | $1.55B |
|
|
|
| Book Value/Share | $22.41 |
| Tangible Book/Share | $-9.61 |
| Equity/Share | $21.91 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | GEHC | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 16.71 | 35.72 | 25% |
| P/B Ratio | 3.69 | 0.19 | 44% |
| ROE (%) | 23.74% | 13.96% | 67% |
| Net Margin (%) | 10.95% | 9.62% | 44% |
| Stock Score | 330 | 471.0 | 0% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GEHC | $80.69 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the GEHC stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc. $GEHC Shares Bought by Anchor Capital Advisors LLC | Neutral | defenseworld.net | Read More |
| GEHC | Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic | Neutral | prnewswire.com | Read More |
| GEHC | Weekly Option Windfall: Leading Medical Imaging Giant Offers Attractive Entry | Negative | zacks.com | Read More |
| GEHC | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | Neutral | reuters.com | Read More |
| GEHC | Sell GE HealthCare Stock, UBS Says. The Risks Aren't Known. | Neutral | barrons.com | Read More |
Recent Insider Trading
No recent insider trading data available for GEHC
Company Information
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
| CEO | Peter J. Arduini |
| Employees | 53000 |
| Country | US |
| IPO Date | 2022-12-15 |
| Exchange | NASDAQ |
| Website | https://www.gehealthcare.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Information Services |
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category